TD Cowen initiated coverage of Mirum Pharmaceuticals (MIRM) with a Buy rating and $95 price target The company has three approved products for rare liver diseases, which are demonstrating strong sales growth, the analyst tells investors in a research note. The firm says Mirum is also advancing volixibat for the treatment of pruritus. TD sees near- and long-term growth with pipeline optionality for the company.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIRM:
- Mirum Pharmaceuticals: Strong Buy Rating Backed by Robust Rare Disease Portfolio and Promising Growth Prospects
- Mirum Pharmaceuticals price target raised to $77 from $53 at JPMorgan
- Mirum Pharmaceuticals completes enrollment in VISTAS study of volixibat
- Mirum Pharmaceuticals’ Volixibat Study: A Potential Game-Changer for PBC Treatment
- Mirum Pharmaceuticals’ Volixibat Study: A Potential Game-Changer for PSC Treatment